Down-regulation of metabolic pathways could offset the poor prognosis conferred by co-existent diabetes mellitus in pancreatic (head) adenocarcinoma.

Gardi, Nilesh; Ketkar, Madhura; McKinnon, Ross A; Pandol, Stephen J; Dutt, Shilpee; Barreto, Savio G

Gardi, Nilesh; Ketkar, Madhura; McKinnon, Ross A; Pandol, Stephen J; Dutt, Shilpee; Barreto, Savio G.

Afiliação

Gardi N; Department of Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Mumbai, India.
Ketkar M; Homi Bhabha National Institute, Mumbai, India.
McKinnon RA; Homi Bhabha National Institute, Mumbai, India.
Pandol SJ; Shilpee Dutt Laboratory, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Mumbai, India.
Dutt S; Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.
Barreto SG; Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, California, USA.

ANZ J Surg ; 91(11): 2466-2474, 2021 11.

Article em En | MEDLINE | ID: mdl-34514690

Assuntos

Adenocarcinoma; Carcinoma Ductal Pancreático; Diabetes Mellitus; Neoplasias Pancreáticas; Adenocarcinoma/genética; Biomarcadores Tumorais/genética; Biomarcadores Tumorais/metabolismo; Carcinoma Ductal Pancreático/genética; Diabetes Mellitus/genética; Regulação para Baixo; Regulação Neoplásica da Expressão Gênica; Humanos; Redes e Vias Metabólicas; Neoplasias Pancreáticas/genética; Prognóstico

Palavras-chave

general surgery; genetics; glucagon; hepatopancreaticobiliary surgery; insulin; pancreas; transcriptome

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Carcinoma Ductal Pancreático / Diabetes Mellitus Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google